APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Generic and Biosimilar Pharmaceuticals

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Generic and Biosimilar Pharmaceuticals Market Outlook and Growth Opportunities 2026

Report ID 173994740431 December 2025204 pages

Choose your research edition.

Industry ResearchGeneric and Biosimilar Pharmaceuticals Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Generic and Biosimilar Pharmaceuticals Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Generic and Biosimilar Pharmaceuticals Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Generic and Biosimilar Pharmaceuticals Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Generic and Biosimilar Pharmaceuticals Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Generic and Biosimilar Pharmaceuticals market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Generic and Biosimilar Pharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Generic and Biosimilar Pharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Generic and Biosimilar Pharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Generic and Biosimilar Pharmaceuticals market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Generic and Biosimilar Pharmaceuticals market include Johnson & Johnson, Novartis, Merck, Roche, Eli Lilly, Pfizer, Amgen, AbbVie and Sanofi-Aventis, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Generic and Biosimilar Pharmaceuticals market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Generic and Biosimilar Pharmaceuticals and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Generic and Biosimilar Pharmaceuticals revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Generic and Biosimilar Pharmaceuticals market.

Generic and Biosimilar Pharmaceuticals Segment by Company

Johnson & Johnson

Novartis

Merck

Roche

Eli Lilly

Pfizer

Amgen

AbbVie

Sanofi-Aventis

Novo Nordisk

Innovent

Gelgen

Ganlee

Dong Bao

CP Guojian

Changchun High Tech

Biotech

3sbio

Generic and Biosimilar Pharmaceuticals Segment by Type

Erythropoietin

Monoclonal Antibodies

Interferon

Insulin

Vaccines

Other

Generic and Biosimilar Pharmaceuticals Segment by Application

Tumor

Hemophilia

Cardiovascular

Diabetes

Other

Generic and Biosimilar Pharmaceuticals Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Generic and Biosimilar Pharmaceuticals status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Generic and Biosimilar Pharmaceuticals key companies, revenue, market share, and recent developments.

3. To split the Generic and Biosimilar Pharmaceuticals breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Generic and Biosimilar Pharmaceuticals market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Generic and Biosimilar Pharmaceuticals significant trends, drivers, influence factors in global and regions.

6. To analyze Generic and Biosimilar Pharmaceuticals competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Generic and Biosimilar Pharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Generic and Biosimilar Pharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Generic and Biosimilar Pharmaceuticals.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Generic and Biosimilar Pharmaceuticals industry.

Chapter 3: Detailed analysis of Generic and Biosimilar Pharmaceuticals company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Generic and Biosimilar Pharmaceuticals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Generic and Biosimilar Pharmaceuticals in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Generic and Biosimilar Pharmaceuticals Industry Trends Table 2. Generic and Biosimilar Pharmaceuticals Industry Drivers Table 3. Generic and Biosimilar Pharmaceuticals Industry Opportunities and Challenges Table 4. Generic and Biosimilar Pharmaceuticals Industry Restraints Table 5. Global Generic and Biosimilar Pharmaceuticals Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Generic and Biosimilar Pharmaceuticals Revenue Share by Company (2021-2026) Table 7. Global Generic and Biosimilar Pharmaceuticals Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Generic and Biosimilar Pharmaceuticals Key Company Manufacturing Base & Headquarters Table 9. Global Generic and Biosimilar Pharmaceuticals Company, Product Type & Application Table 10. Global Generic and Biosimilar Pharmaceuticals Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Generic and Biosimilar Pharmaceuticals by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Erythropoietin Table 15. Significant Companies of Monoclonal Antibodies Table 16. Significant Companies of Interferon Table 17. Significant Companies of Insulin Table 18. Significant Companies of Vaccines Table 19. Significant Companies of Other Table 20. Global Generic and Biosimilar Pharmaceuticals Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 21. Global Generic and Biosimilar Pharmaceuticals Sales Value by Type (2021-2026) & (US$ Million) Table 22. Global Generic and Biosimilar Pharmaceuticals Sales Value by Type (2027-2032) & (US$ Million) Table 23. Global Generic and Biosimilar Pharmaceuticals Sales Value Share by Type (2021-2026) Table 24. Global Generic and Biosimilar Pharmaceuticals Sales Value Share by Type (2027-2032) Table 25. Significant Companies of Tumor Table 26. Significant Companies of Hemophilia Table 27. Significant Companies of Cardiovascular Table 28. Significant Companies of Diabetes Table 29. Significant Companies of Other Table 30. Global Generic and Biosimilar Pharmaceuticals Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Generic and Biosimilar Pharmaceuticals Sales Value by Application (2021-2026) & (US$ Million) Table 32. Global Generic and Biosimilar Pharmaceuticals Sales Value by Application (2027-2032) & (US$ Million) Table 33. Global Generic and Biosimilar Pharmaceuticals Sales Value Share by Application (2021-2026) Table 34. Global Generic and Biosimilar Pharmaceuticals Sales Value Share by Application (2027-2032) Table 35. Global Generic and Biosimilar Pharmaceuticals Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Generic and Biosimilar Pharmaceuticals Sales Value by Region (2021-2026) & (US$ Million) Table 37. Global Generic and Biosimilar Pharmaceuticals Sales Value Share by Region (2021-2026) Table 38. Global Generic and Biosimilar Pharmaceuticals Sales Value by Region (2027-2032) & (US$ Million) Table 39. Global Generic and Biosimilar Pharmaceuticals Sales Value Share by Region (2027-2032) Table 40. Global Generic and Biosimilar Pharmaceuticals Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Generic and Biosimilar Pharmaceuticals Sales Value by Country (2021-2026) & (US$ Million) Table 42. Global Generic and Biosimilar Pharmaceuticals Sales Value Market Share by Country (2021-2026) Table 43. Global Generic and Biosimilar Pharmaceuticals Sales Value by Country (2027-2032) & (US$ Million) Table 44. Global Generic and Biosimilar Pharmaceuticals Sales Value Market Share by Country (2027-2032) Table 45. Johnson & Johnson Company Information Table 46. Johnson & Johnson Business Overview Table 47. Johnson & Johnson Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Johnson & Johnson Generic and Biosimilar Pharmaceuticals Product Portfolio Table 49. Johnson & Johnson Recent Development Table 50. Novartis Company Information Table 51. Novartis Business Overview Table 52. Novartis Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Novartis Generic and Biosimilar Pharmaceuticals Product Portfolio Table 54. Novartis Recent Development Table 55. Merck Company Information Table 56. Merck Business Overview Table 57. Merck Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Merck Generic and Biosimilar Pharmaceuticals Product Portfolio Table 59. Merck Recent Development Table 60. Roche Company Information Table 61. Roche Business Overview Table 62. Roche Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Roche Generic and Biosimilar Pharmaceuticals Product Portfolio Table 64. Roche Recent Development Table 65. Eli Lilly Company Information Table 66. Eli Lilly Business Overview Table 67. Eli Lilly Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Eli Lilly Generic and Biosimilar Pharmaceuticals Product Portfolio Table 69. Eli Lilly Recent Development Table 70. Pfizer Company Information Table 71. Pfizer Business Overview Table 72. Pfizer Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Pfizer Generic and Biosimilar Pharmaceuticals Product Portfolio Table 74. Pfizer Recent Development Table 75. Amgen Company Information Table 76. Amgen Business Overview Table 77. Amgen Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Amgen Generic and Biosimilar Pharmaceuticals Product Portfolio Table 79. Amgen Recent Development Table 80. AbbVie Company Information Table 81. AbbVie Business Overview Table 82. AbbVie Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. AbbVie Generic and Biosimilar Pharmaceuticals Product Portfolio Table 84. AbbVie Recent Development Table 85. Sanofi-Aventis Company Information Table 86. Sanofi-Aventis Business Overview Table 87. Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Product Portfolio Table 89. Sanofi-Aventis Recent Development Table 90. Novo Nordisk Company Information Table 91. Novo Nordisk Business Overview Table 92. Novo Nordisk Generic and Biosimilar Pharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Novo Nordisk Generic and Biosimilar Pharmaceuticals Product Portfolio Table 94. Novo Nordisk Recent Development Table 95. Innovent Company Information Table 96. Innovent Business Overview Table 97. Innovent Generic and Biosimilar Pharmaceuticals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Innovent Generic and Biosimilar Pharmaceuticals Product Portfolio Table 99. Innovent Recent Development Table 100. Gelgen Company Information Table 101. Gelgen Business Overview Table 102. Gelgen Generic and Biosimilar Pharmaceuticals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Gelgen Generic and Biosimilar Pharmaceuticals Product Portfolio Table 104. Gelgen Recent Development Table 105. Ganlee Company Information Table 106. Ganlee Business Overview Table 107. Ganlee Generic and Biosimilar Pharmaceuticals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Ganlee Generic and Biosimilar Pharmaceuticals Product Portfolio Table 109. Ganlee Recent Development Table 110. Dong Bao Company Information Table 111. Dong Bao Business Overview Table 112. Dong Bao Generic and Biosimilar Pharmaceuticals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Dong Bao Generic and Biosimilar Pharmaceuticals Product Portfolio Table 114. Dong Bao Recent Development Table 115. CP Guojian Company Information Table 116. CP Guojian Business Overview Table 117. CP Guojian Generic and Biosimilar Pharmaceuticals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. CP Guojian Generic and Biosimilar Pharmaceuticals Product Portfolio Table 119. CP Guojian Recent Development Table 120. Changchun High Tech Company Information Table 121. Changchun High Tech Business Overview Table 122. Changchun High Tech Generic and Biosimilar Pharmaceuticals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Changchun High Tech Generic and Biosimilar Pharmaceuticals Product Portfolio Table 124. Changchun High Tech Recent Development Table 125. Biotech Company Information Table 126. Biotech Business Overview Table 127. Biotech Generic and Biosimilar Pharmaceuticals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Biotech Generic and Biosimilar Pharmaceuticals Product Portfolio Table 129. Biotech Recent Development Table 130. 3sbio Company Information Table 131. 3sbio Business Overview Table 132. 3sbio Generic and Biosimilar Pharmaceuticals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. 3sbio Generic and Biosimilar Pharmaceuticals Product Portfolio Table 134. 3sbio Recent Development Table 135. Research Programs/Design for This Report Table 136. Authors List of This Report Table 137. Secondary Sources Table 138. Primary Sources List of Figures Figure 1. Generic and Biosimilar Pharmaceuticals Product Image Figure 2. Global Generic and Biosimilar Pharmaceuticals Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Generic and Biosimilar Pharmaceuticals Market Size (2021-2032) & (US$ Million) Figure 4. Global Generic and Biosimilar Pharmaceuticals Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Erythropoietin Image Figure 8. Monoclonal Antibodies Image Figure 9. Interferon Image Figure 10. Insulin Image Figure 11. Vaccines Image Figure 12. Other Image Figure 13. Global Generic and Biosimilar Pharmaceuticals Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 14. Global Generic and Biosimilar Pharmaceuticals Sales Value Share 2021 VS 2025 VS 2032 Figure 15. Global Generic and Biosimilar Pharmaceuticals Sales Value Share by Type (2021-2032) Figure 16. Tumor Image Figure 17. Hemophilia Image Figure 18. Cardiovascular Image Figure 19. Diabetes Image Figure 20. Other Image Figure 21. Global Generic and Biosimilar Pharmaceuticals Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Generic and Biosimilar Pharmaceuticals Sales Value Share 2021 VS 2025 VS 2032 Figure 23. Global Generic and Biosimilar Pharmaceuticals Sales Value Share by Application (2021-2032) Figure 24. Global Generic and Biosimilar Pharmaceuticals Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 25. Global Generic and Biosimilar Pharmaceuticals Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 26. North America Generic and Biosimilar Pharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 27. North America Generic and Biosimilar Pharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Europe Generic and Biosimilar Pharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 29. Europe Generic and Biosimilar Pharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Asia-Pacific Generic and Biosimilar Pharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 31. Asia-Pacific Generic and Biosimilar Pharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 32. South America Generic and Biosimilar Pharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 33. South America Generic and Biosimilar Pharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Middle East & Africa Generic and Biosimilar Pharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 35. Middle East & Africa Generic and Biosimilar Pharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 36. USA Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. USA Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. USA Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Canada Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Canada Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Canada Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Mexico Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Mexico Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Mexico Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Germany Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Germany Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Germany Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. France Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. France Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. France Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. U.K. Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. U.K. Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. U.K. Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Italy Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Italy Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Italy Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Spain Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Spain Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Spain Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Russia Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Russia Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Russia Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Netherlands Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Netherlands Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Netherlands Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Nordic Countries Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Nordic Countries Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Nordic Countries Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. China Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. China Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. China Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Japan Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Japan Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Japan Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. South Korea Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. South Korea Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. South Korea Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. India Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. India Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. India Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Australia Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Australia Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Australia Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Southeast Asia Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Southeast Asia Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Southeast Asia Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Brazil Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Brazil Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Brazil Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Argentina Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Argentina Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Argentina Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Chile Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Chile Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Chile Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Colombia Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Colombia Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Colombia Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Peru Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Peru Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Peru Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Saudi Arabia Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Saudi Arabia Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Israel Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Israel Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Israel Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. UAE Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. UAE Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. UAE Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Turkey Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Turkey Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Turkey Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Iran Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Iran Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Iran Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Egypt Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Egypt Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Egypt Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Years Considered Figure 121. Research Process Figure 122. Key Executives Interviewed

Scope & coverage.

Types
  • Erythropoietin
  • Monoclonal Antibodies
  • Interferon
  • Insulin
  • Vaccines
  • Other
Applications
  • Tumor
  • Hemophilia
  • Cardiovascular
  • Diabetes
  • Other
Companies covered
  • Johnson & Johnson
  • Novartis
  • Merck
  • Roche
  • Eli Lilly
  • Pfizer
  • Amgen
  • AbbVie
  • Sanofi-Aventis
  • Novo Nordisk
  • Innovent
  • Gelgen
  • Ganlee
  • Dong Bao
  • CP Guojian
  • Changchun High Tech
  • Biotech
  • 3sbio

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Generic and Biosimilar Pharmaceuticals Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Generic and Biosimilar Pharmaceuticals Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Generic and Biosimilar Pharmaceuticals Market Dynamics
  1. 2.1 Generic and Biosimilar Pharmaceuticals Industry Trends
  2. 2.2 Generic and Biosimilar Pharmaceuticals Industry Drivers
  3. 2.3 Generic and Biosimilar Pharmaceuticals Industry Opportunities and Challenges
  4. 2.4 Generic and Biosimilar Pharmaceuticals Industry Restraints
3 Generic and Biosimilar Pharmaceuticals Market by Company
  1. 3.1 Global Generic and Biosimilar Pharmaceuticals Company Revenue Ranking in 2025
  2. 3.2 Global Generic and Biosimilar Pharmaceuticals Revenue by Company (2021-2026)
  3. 3.3 Global Generic and Biosimilar Pharmaceuticals Company Ranking (2024-2026)
  4. 3.4 Global Generic and Biosimilar Pharmaceuticals Company Manufacturing Base and Headquarters
  5. 3.5 Global Generic and Biosimilar Pharmaceuticals Company Product Type and Application
  6. 3.6 Global Generic and Biosimilar Pharmaceuticals Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Generic and Biosimilar Pharmaceuticals Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Generic and Biosimilar Pharmaceuticals Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Generic and Biosimilar Pharmaceuticals Market by Type
  1. 4.1 Generic and Biosimilar Pharmaceuticals Type Introduction
  2. 4.1.1 Erythropoietin
  3. 4.1.2 Monoclonal Antibodies
  4. 4.1.3 Interferon
  5. 4.1.4 Insulin
  6. 4.1.5 Vaccines
  7. 4.1.6 Other
  8. 4.2 Global Generic and Biosimilar Pharmaceuticals Sales Value by Type
  9. 4.2.1 Global Generic and Biosimilar Pharmaceuticals Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Generic and Biosimilar Pharmaceuticals Sales Value by Type (2021-2032)
  11. 4.2.3 Global Generic and Biosimilar Pharmaceuticals Sales Value Share by Type (2021-2032)
5 Generic and Biosimilar Pharmaceuticals Market by Application
  1. 5.1 Generic and Biosimilar Pharmaceuticals Application Introduction
  2. 5.1.1 Tumor
  3. 5.1.2 Hemophilia
  4. 5.1.3 Cardiovascular
  5. 5.1.4 Diabetes
  6. 5.1.5 Other
  7. 5.2 Global Generic and Biosimilar Pharmaceuticals Sales Value by Application
  8. 5.2.1 Global Generic and Biosimilar Pharmaceuticals Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Generic and Biosimilar Pharmaceuticals Sales Value by Application (2021-2032)
  10. 5.2.3 Global Generic and Biosimilar Pharmaceuticals Sales Value Share by Application (2021-2032)
6 Generic and Biosimilar Pharmaceuticals Regional Value Analysis
  1. 6.1 Global Generic and Biosimilar Pharmaceuticals Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Generic and Biosimilar Pharmaceuticals Sales Value by Region (2021-2032)
  3. 6.2.1 Global Generic and Biosimilar Pharmaceuticals Sales Value by Region: 2021-2026
  4. 6.2.2 Global Generic and Biosimilar Pharmaceuticals Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Generic and Biosimilar Pharmaceuticals Sales Value (2021-2032)
  7. 6.3.2 North America Generic and Biosimilar Pharmaceuticals Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Generic and Biosimilar Pharmaceuticals Sales Value (2021-2032)
  10. 6.4.2 Europe Generic and Biosimilar Pharmaceuticals Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Generic and Biosimilar Pharmaceuticals Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Generic and Biosimilar Pharmaceuticals Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Generic and Biosimilar Pharmaceuticals Sales Value (2021-2032)
  16. 6.6.2 South America Generic and Biosimilar Pharmaceuticals Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Generic and Biosimilar Pharmaceuticals Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Generic and Biosimilar Pharmaceuticals Sales Value Share by Country, 2025 VS 2032
7 Generic and Biosimilar Pharmaceuticals Country-level Value Analysis
  1. 7.1 Global Generic and Biosimilar Pharmaceuticals Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Generic and Biosimilar Pharmaceuticals Sales Value by Country (2021-2032)
  3. 7.2.1 Global Generic and Biosimilar Pharmaceuticals Sales Value by Country (2021-2026)
  4. 7.2.2 Global Generic and Biosimilar Pharmaceuticals Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Generic and Biosimilar Pharmaceuticals Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Generic and Biosimilar Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Generic and Biosimilar Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Johnson & Johnson
  2. 8.1.1 Johnson & Johnson Company Information
  3. 8.1.2 Johnson & Johnson Business Overview
  4. 8.1.3 Johnson & Johnson Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Johnson & Johnson Generic and Biosimilar Pharmaceuticals Product Portfolio
  6. 8.1.5 Johnson & Johnson Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Generic and Biosimilar Pharmaceuticals Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck Generic and Biosimilar Pharmaceuticals Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 Roche
  20. 8.4.1 Roche Company Information
  21. 8.4.2 Roche Business Overview
  22. 8.4.3 Roche Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Roche Generic and Biosimilar Pharmaceuticals Product Portfolio
  24. 8.4.5 Roche Recent Developments
  25. 8.5 Eli Lilly
  26. 8.5.1 Eli Lilly Company Information
  27. 8.5.2 Eli Lilly Business Overview
  28. 8.5.3 Eli Lilly Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Eli Lilly Generic and Biosimilar Pharmaceuticals Product Portfolio
  30. 8.5.5 Eli Lilly Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Generic and Biosimilar Pharmaceuticals Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Amgen
  38. 8.7.1 Amgen Company Information
  39. 8.7.2 Amgen Business Overview
  40. 8.7.3 Amgen Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Amgen Generic and Biosimilar Pharmaceuticals Product Portfolio
  42. 8.7.5 Amgen Recent Developments
  43. 8.8 AbbVie
  44. 8.8.1 AbbVie Company Information
  45. 8.8.2 AbbVie Business Overview
  46. 8.8.3 AbbVie Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2021-2026)
  47. 8.8.4 AbbVie Generic and Biosimilar Pharmaceuticals Product Portfolio
  48. 8.8.5 AbbVie Recent Developments
  49. 8.9 Sanofi-Aventis
  50. 8.9.1 Sanofi-Aventis Company Information
  51. 8.9.2 Sanofi-Aventis Business Overview
  52. 8.9.3 Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Product Portfolio
  54. 8.9.5 Sanofi-Aventis Recent Developments
  55. 8.10 Novo Nordisk
  56. 8.10.1 Novo Nordisk Company Information
  57. 8.10.2 Novo Nordisk Business Overview
  58. 8.10.3 Novo Nordisk Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Novo Nordisk Generic and Biosimilar Pharmaceuticals Product Portfolio
  60. 8.10.5 Novo Nordisk Recent Developments
  61. 8.11 Innovent
  62. 8.11.1 Innovent Company Information
  63. 8.11.2 Innovent Business Overview
  64. 8.11.3 Innovent Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Innovent Generic and Biosimilar Pharmaceuticals Product Portfolio
  66. 8.11.5 Innovent Recent Developments
  67. 8.12 Gelgen
  68. 8.12.1 Gelgen Company Information
  69. 8.12.2 Gelgen Business Overview
  70. 8.12.3 Gelgen Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Gelgen Generic and Biosimilar Pharmaceuticals Product Portfolio
  72. 8.12.5 Gelgen Recent Developments
  73. 8.13 Ganlee
  74. 8.13.1 Ganlee Company Information
  75. 8.13.2 Ganlee Business Overview
  76. 8.13.3 Ganlee Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Ganlee Generic and Biosimilar Pharmaceuticals Product Portfolio
  78. 8.13.5 Ganlee Recent Developments
  79. 8.14 Dong Bao
  80. 8.14.1 Dong Bao Company Information
  81. 8.14.2 Dong Bao Business Overview
  82. 8.14.3 Dong Bao Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Dong Bao Generic and Biosimilar Pharmaceuticals Product Portfolio
  84. 8.14.5 Dong Bao Recent Developments
  85. 8.15 CP Guojian
  86. 8.15.1 CP Guojian Company Information
  87. 8.15.2 CP Guojian Business Overview
  88. 8.15.3 CP Guojian Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2021-2026)
  89. 8.15.4 CP Guojian Generic and Biosimilar Pharmaceuticals Product Portfolio
  90. 8.15.5 CP Guojian Recent Developments
  91. 8.16 Changchun High Tech
  92. 8.16.1 Changchun High Tech Company Information
  93. 8.16.2 Changchun High Tech Business Overview
  94. 8.16.3 Changchun High Tech Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Changchun High Tech Generic and Biosimilar Pharmaceuticals Product Portfolio
  96. 8.16.5 Changchun High Tech Recent Developments
  97. 8.17 Biotech
  98. 8.17.1 Biotech Company Information
  99. 8.17.2 Biotech Business Overview
  100. 8.17.3 Biotech Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Biotech Generic and Biosimilar Pharmaceuticals Product Portfolio
  102. 8.17.5 Biotech Recent Developments
  103. 8.18 3sbio
  104. 8.18.1 3sbio Company Information
  105. 8.18.2 3sbio Business Overview
  106. 8.18.3 3sbio Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2021-2026)
  107. 8.18.4 3sbio Generic and Biosimilar Pharmaceuticals Product Portfolio
  108. 8.18.5 3sbio Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst